Mayo Clinic Collaborates with SHL Telemedicine using SmartHeart™ Technology 12 lead ECG Mittwoch, 14. Oktober 2020 - 07:00

Press release

Study intends to evaluate the use of home telemonitoring SmartHeart technology to decrease hospital visits and lower healthcare utilization costs

Tel Aviv / Zurich / Newton MA, 14 October 2020 – Mayo Clinic and SHL Telemedicine Ltd., today announced a collaboration to evaluate the incidence of emergency department visits, re-hospitalizations and MACE (major adverse cardiovascular events), and cost–effectiveness over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG, the golden standard ECG for diagnosing heart attack.

The central hypothesis is that the use of SmartHeart 12 lead ECG home telemonitoring by patients may decrease general and cardiac emergency department presentation and hospital readmission rates without an increase in MACE, and at a lower healthcare utilization cost compared to patients with standard therapy alone.

“We have seen the clinical benefits to patients as well as efficient use of healthcare resources by institutions using SHL’s patented SmartHeart technology, and this collaboration presents an opportunity to broaden our knowledge in the U.S. market,” said Erez Nachtomy, CEO of SHL Telemedicine. “We believe our SmartHeart technology could have important clinical implications for telemedicine and remote patient monitoring in the very near future. We are excited to work with Mayo Clinic."

For further information please contact:

Martin Meier-Pfister, IRF, Phone: +41 43 244 81 40, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.